HTG2014-Section-Header-publications

Categories

Filter by Topics

ALK Apoptosis Asthma Autocrine Signaling B Cells benign Biofluid Biomarker Analysis Biomarker Discovery Biomarker Validation Biomarkers Bladder Cancer Breast Cancer Breast milk Cancer Genomics Cells Cerebrospinal Fluid Childhood Atopic Dermatitis Chronic Obstructive Pulmonary Disease Circulating miRNAs Colorectal cancer Comparative Study Comparison study computational toxicology Core Needle Biopsy COVID-19 Custom mRNA Cytokines Cytotoxic T Cells Dementia Diabetes Differential Expression Differential Gene Expression Analysis DLBCL Drug Response Drug Safety Drug Targets Drug-induced Liver Injury EGFR Muatations EMT epidemiology epigenomics Epstein-Barr Esophageal Cancer Exosomes Extracellular Vesicles Fabry Disease Feasibility FFPE FGF Ligand Trap Fibrous Tumors Gene Expression Profiling Gene Signature Analysis Glioblastoma Tumors Head and Neck Cancer Heart HTG EdgeSeq ALKPlus Assay EU HTG EdgeSeq Custom Assays HTG EdgeSeq DLBCL Cell of Origin Assay HTG EdgeSeq DLBCL-COO-CE-IVD HTG EdgeSeq Immune Response Panel HTG EdgeSeq Immuno-Oncology Assay HTG EdgeSeq miRNA Whole Transcriptome Assay HTG EdgeSeq miRNA Whole Transcriptome Panel HTG EdgeSeq Mouse mRNA Tumor Response Panel HTG EdgeSeq Oncology Biomarker Panel HTG EdgeSeq Path Assay HTG EdgeSeq Precision Immuno-Oncology Panel HTG EdgeSeq Precision Immunol-Oncology Panel HTG EdgeSeq System HTG EdgeSeq System Oncology Biomarker Panel HTG EdgSeq Immuno-Oncology Assay ibrutinib Immune Checkpoint Inhibitors Immune Related Genes Immune Response Immune Tolerance Immuno-Oncology immunohistochemistry IHC Immunotherapy Inflammation Juvenile Arthritis Kidney Liquid Biopsy Liver Lung Lung cancer Lymph Node Metastasis Lymphoma machine learning malignant Mechanism of Action Melanoma Mesothelioma Microenvironment MicroRNA miRNA Molecular Characterization Mouse mRNA custom mTOR pathway multi-omics Muscle Mutations NAFLD Nash and Fibrosis Neoantigens Neuroendocrine Tumor Neurologic Oncology Oral Cancer Osteoclast Ovarian cancer Pancreas Paralysis Pathogenesis Pathway analysis Pathway Analysis PCA Cell Lines PD-1 PD-L1 placenta Placenta Plasma predictive biology Predictive Biomarkers Predictive Modeling Progression free-survival Prostate Prostate Cancer qNPA Reproductive Response rate Reveal Rheumatoid Arthritis Risk Score Sarcoma Serum Signaling Inhibitors Signatures Sinonasal Carcinoma Skin SPECS Lung Consortium Squamous cell carcinoma Sub-typing surface plasmon Surveillance Survival Outcomes Synovial Fluid synthetic miRNA T-Cell T-cells Technology Comparison Therapeutic targets Thyroid Cancer TMB Toxicity Translational Medicine Treatment Outcome Tumor Biology Tumor Heterogeneity Tumor Microenvironment Urothelial carcinoma Uterus Wound healing Xenograft Tissue

2020

Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined replapsed or refractory diffuse large B-cell lymphoma

Lenz, G., et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined replapsed or refractory diffuse large B-cell lymphoma. Leukemia 2020 (34) 2184-2197. https://doi.org/10.1038/s41375-020-0743-y

Download pdf 848KB

Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer

Finn, R. S., et al. Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Woment with Treatment-Naïve Metastatic Breast Cancer. Clinical Cancer Research | Precision Medicine and Imaging. 2020 Jan 15. 26:110-21. DOI: 10.1158/1078-0432.CCR-19-0751.

Download pdf 1.4MB

2019

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma

Younes, A., et al. Journal of Clinical Oncology 2019 Mar22;37(15):1285-1295. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Download pdf 1.2MB

Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with baseline Metabolic Tumor volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial.

Richter, J., et al. Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial. Blood Cancer Journal 2019 Aug 19; 9(67).

Download pdf 757KB

Transcriptomic and Protein Analysis of Small-cell Baldder Cancer (SCBC) Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target.

Koshkin, V. S., et al. Transcriptomic and Protein Analysis of Small-cell Bladder Cancer  Identifies Prognostic Biomarkers and DLL3 as a Relevant Therapeutic Target. Clinical Cancer Research. 2019 Jan 1; 25(1) 210-221.

Download pdf 7.4MB

2018

Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples.

Schaffer, M., et al. Comparison of Immunohistochemistry Assay Results with Gene Expression Profiling Methods for Diffuse Large B-Cell Lymphoma Subtype Identification in Matched Patient Samples. J Mol Biomark Diagn 2018, 9:2 DOI: 10.4172/2155-9929.1000386

Download pdf 1.3MB

2017

The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade

Foy JP., et al. The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade. Ann Oncol. 2017 Aug 1; 28(8):1934

PMID: 28460011

View External Link

2015

Page last updated September 16, 2021